Drug Trial Radar · NCT02876900
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
617
Actual
Start
Aug 2016
Primary completion
Jun 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- Noven Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.
Conditions
- Schizophrenia
Interventions
Low Dose Asenapine maleate transdermal patchDrug
The study will evaluate low dose Asenapine maleate transdermal patch
High Dose Asenapine maleate transdermal patchDrug
The study will evaluate high dose Asenapine maleate transdermal patch
PlaceboDrug
The study will evaluate placebo transdermal patch.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale (PANSS) Total Score: Change From Baseline to Week 6.Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Noven Pharmaceuticals, Inc.
Jersey City, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.